Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10298265 | 0.86 | POLB (0.37) | ALDH1A1HSD17B10KMT2AKDM4EMAPK1 | |
| SCHEMBL11903992 | 0.76 | LMNA (0.34) | ALDH1A1KDM4EMAPK1CYP1A2TDP1 | |
| SCHEMBL1613433 | 0.72 | HSD17B10 (0.36) | ALDH1A1HSD17B10KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL9517798 | 0.69 | ALDH1A1 (0.39) | ALDH1A1HSD17B10KMT2AKDM4EMAPT | |
| SCHEMBL7825017 | 0.67 | ALDH1A1 (0.34) | ALDH1A1HSD17B10KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5848990 | 0.66 | ALDH1A1 (0.51) | ALDH1A1HSD17B10KMT2AKDM4ECYP1A2 | |
| SCHEMBL20669696 | 0.64 | PIK3CG (0.51) | ALDH1A1HSD17B10KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL7373297 | 0.64 | POLB (0.39) | ALDH1A1HSD17B10KMT2ACYP1A2TDP1 | |
| SCHEMBL683558 | 0.63 | THRB (0.44) | ALDH1A1HSD17B10KMT2AKDM4ECYP1A2 | |
| SCHEMBL683499 | 0.62 | POLB (0.38) | ALDH1A1HSD17B10KMT2ACYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499630-A1 | BCL-XL INHIBITORS | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034128-A1 | BCL-XL INHIBITORS | BEIGENE, LTD. (KY) | 2025-01-30 | — | — | US | disclosed |
| CN-118974033-A | Bcl-xL inhibitors | 百济神州有限公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023185986-A1 | BCL-XL INHIBITORS | BEIGENE , LTD. (KY) | 2023-10-05 | — | — | WO | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-7229480-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| EP-0433855-B1 | N- and O-substituted aminophenol derivatives, intermediates for their preparation, their use as hydrolase substrates, a corresponding assay and diagnostic agents | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-07 | — | — | EP | disclosed |
| EP-0433854-B1 | 3-Aminopyrazolo heterocycles, their use for the determination of hydrogen peroxide, hydrogen peroxide forming systems, peroxidase, peroxidant active substances or electron rich aromatic compounds, corresponding determination process and agents | BOEHRINGER MANNHEIM GMBH (DE) | 1997-06-18 | — | — | EP | disclosed |
| US-5525480-A | USED FOR DETERMINATION OF HYDROLASES; COLORIMETRIC ANALYSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1996-06-11 | — | — | US | disclosed |
| US-5457200-A | Oxidative coupling reactions for determination of hydrogen peroxide | BOEHRINGER MANNHEIM (DE) | 1995-10-10 | — | — | US | disclosed |
| US-5334505-A | For colorimetric determination of hydrolases | BOEHRINGER MANNHEIM GMBH (DE) | 1994-08-02 | — | — | US | disclosed |
| US-5234818-A | Detecting hydrogen peroxide, peroxidase by oxidative coupling with electron-rich aromatic compound | BOEHRINGER MANNHEIM GMBH (DE) | 1993-08-10 | — | — | US | disclosed |
| EP-0433854-A2 | 3-Aminopyrazolo heterocycles, their use for the determination of hydrogen peroxide, hydrogen peroxide forming systems, peroxidase, peroxidant active substances or electron rich aromatic compounds, corresponding determination process and agents | Roche Diagnostics GmbH (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0433855-A2 | N- and O-substituted aminophenol derivatives, intermediates for their preparation, their use as hydrolase substrates, a corresponding assay and diagnostic agents | Roche Diagnostics GmbH (DE) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034128-A1 | BCL-XL INHIBITORS | BCL2, BCL2L1, BCL2L10 | ALDH1A1 2996/4885HSD17B10 1525/4885KMT2A 3308/4885 |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | ALDH1A1 395/4885HSD17B10 405/4885KMT2A 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.